<DOC>
	<DOC>NCT01617213</DOC>
	<brief_summary>This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.</brief_summary>
	<brief_title>Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Must be 18 to 75 years of age. ECOG performance status of 0, 1 or 2. Patients who have a history of another malignant disorder are eligible, provided that they have not received active therapy for 5 years. Patients with basal cell and squamous cell skin cancers are eligible. Patients who are pregnant are ineligible. Patients must furnish written informed consent and HIPAA authorization for release of personal health information. Patients must be able to understand the requirements of the study, abide by the study restrictions, and agree to return for the required assessments. Patients must be HIV and HTLVI,II antibody seronegative. Patients must have adequate visceral organ function Patients are ineligible if they have received cumulative chemotherapy doses in excess of: carmustine (BCNU) 400 mg/m2, or a cumulative anthracycline exposure in excess of 550 mg/m2 Adriamycin (doxorubicin) unless the gatedpool radionuclide cardiac scan shows greater than/equal to 45% ejection fraction. Patients are ineligible if they are receiving any other investigational agents.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>